Ribox® 60 tablet: Each tablet contains Etoricoxib INN 60 mg.
Ribox® 90 tablet: Each tablet contains Etoricoxib INN 90 mg.
Ribox® 120 tablet: Each tablet contains Etoricoxib INN 120 mg.
Etoricoxib is a COX-2 selective inhibitor which is 106.0 times more selective for COX-2 inhibition over COX-1.
Osteoarthritis: The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.
Rheumatoid arthritis: The recommended dose is 90 mg once daily.
Acute gouty arthritis: The recommended dose is 120 mg once daily. Etoricoxib 120 mg should be used only for the acute symptomatic period. In clinical trials for acute gouty arthritis, Etoricoxib was given for 8 days.
Ankylosing spondylitis: The recommended dose is 90 mg once daily.
Elderly: No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients.
Paediatric patients: Etoricoxib is contraindicated in children and adolescents under 16 years of age.
Oral anticoagulants, diuretics and ACE inhibitors, Acetylsalicylic acid, Cyclosporin and Tacrolimus, Lithium, Methotrexate, oral contraceptives, Prednisone/Prednisolone, Digoxin, drugs metabolized by sulfotransferases (Ethynyl Estradiol), drugs metabolized by CYP isoenzymes, Ketoconazole, Rifampicin, and Antacids have interaction with Etoricoxib.
Overdose
Administration of single doses of Etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the GI tract, employ clinical monitoring, and institute supportive therapy, if required.
Dry mouth, taste disturbance, mouth ulcers, flatulence, constipation, appetite and weight changes, chest pain, fatigue, paraesthesia, influenza-like syndrome & myalgia.
The use of Etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive. As Etoricoxib is excreted in the milk of lactating rats so women who use Etoricoxib must not breast feed.
Upper gastrointestinal complications like perforations, ulcers or bleedings (PUBs) occurred in patients treated with Etoricoxib. COX-2 inhibitor may be associated with a risk of thrombotic events (especially myocardial infarction and stroke), relative to placebo and some NSAIDs. Under conditions of compromised renal perfusion, administration of Etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention, oedema and hypertension have been observed in patients taking Etoricoxib. Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) have been reported in approximately 1% of patients in clinical trials treated for up to one year with Etoricoxib 30, 60 and 90 mg daily. Skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs and some selective COX-2 inhibitors during post-marketing.
Store in cool & dry place, away from children.